Ulysses Management’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-50,000
Closed -$1.83M 55
2023
Q2
$1.83M Buy
+50,000
New +$1.95M 0.17% 29
2017
Q1
Sell
-26,350
Closed -$812K 47
2016
Q4
$812K Sell
26,350
-15,810
-38% -$483K 0.13% 38
2016
Q3
$1.35M Sell
42,160
-10,540
-20% -$352K 0.16% 39
2016
Q2
$1.76M Hold
52,700
0.21% 33
2016
Q1
$1.48M Hold
52,700
0.16% 42
2015
Q4
$1.61M Sell
52,700
-31,620
-38% -$995K 0.2% 43
2015
Q3
$2.51M Buy
+84,320
New +$2.7M 0.27% 35

Other funds holding PFE

Ulysses Management's PFE Position: Q3 2023 in Review

Ulysses Management sold out of Pfizer (PFE) in Q3 2023, closing a stake of 40,000 shares — an estimated $1.47M sold.

Ulysses Management first reported a position in PFE in Q1 2023 and held it in 2 quarters. The position peaked at $1.63M in Q1 2023. 2,925 funds tracked by Wall St. Rank hold PFE as of Q3 2023.

  • Ulysses Management reported no remaining Pfizer position as of Q3 2023 after selling out during the quarter.
  • Ulysses Management sold 40,000 Pfizer shares in Q3 2023, an estimated $1.47M.
  • Ulysses Management first reported a position in Pfizer in Q1 2023 and held it in 2 quarters.
  • Ulysses Management's Pfizer position peaked at $1.63M in Q1 2023.
  • 2,925 funds tracked by Wall St. Rank held Pfizer as of Q3 2023.

Based on Ulysses Management's 13F filing for Q3 2023, filed 14 Nov 2023.